Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KCNH3 | Q9ULD8 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24312364 | 0.89 | SMN1; SMN2 (0.40) | CYP3A4HTTSMN1; SMN2SMYD2CA2 | |
| SCHEMBL9572212 | 0.86 | CYP3A4 (0.42) | CYP3A4HTTSMN1; SMN2SMYD2CA2 | |
| SCHEMBL21176568 | 0.84 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL706843 | 0.83 | SMYD2 (0.40) | CYP3A4HTTSMN1; SMN2SMYD2ALDH1A1 | |
| SCHEMBL25347656 | 0.83 | SMYD2 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2ALDH1A1 | |
| SCHEMBL23461733 | 0.82 | SMN1; SMN2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2CA2 | |
| SCHEMBL1316789 | 0.81 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL1726263 | 0.81 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2TDP1 | |
| SCHEMBL8194768 | 0.81 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL453430 | 0.81 | SMN1; SMN2 (0.44) | CYP3A4HTTSMN1; SMN2SMYD2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2759538-B1 | RADIOACTIVE FLUORINE LABELED COMPOUND | NIHON MEDIPHYSICS CO LTD (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-9107964-B2 | Radioactive fluorine-labeled compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20140364620-A1 | RADIOACTIVE FLUORINE-LABELED COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2014-12-11 | — | — | US | disclosed |
| US-6194396-B1 | ANTIALLERGENS; ANTIINFLAMMATION AGENTS; AUTOIMMUNE DISEASE; ANTISHOCK AGENTS; ANALGESICS; E.G., A 4 OR 7-PHENYLALKYLENE-OXYBENZIMIDAZOLE UNSUBSTITUTED OR SUBSTITUTED IN THE 1,2,3-POSITION WITH AN OXY, AMINO AND/OR THIO GROUP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| US-6083961-A | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364620-A1 | RADIOACTIVE FLUORINE-LABELED COMPOUND | AFF1, PRMT1, DOT1L | CYP3A4 1827/4885HTT 1056/4885SMN1; SMN2 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.